---
id: 182
title: Neutropenic Fever Management
category: special_populations
subcategory: immunocompromised
tags: [neutropenic-fever, febrile-neutropenia, chemotherapy, cefepime, vancomycin, GCSF]
difficulty: high
---

## Question

How is neutropenic fever managed? Use **"ANC <500 + Fever → Cefepime (Mono) or +Vanc (Unstable/Skin), Add Antifungal if Persistent >4-7d"** framework.

## Answer

### **Definition:**
- **Neutropenic fever:** Single temperature ≥38.3°C (101°F) OR ≥38°C (100.4°F) × ≥1h + ANC <500 (or <1000 and expected to decline <500)

### **Empiric Antibiotics (Immediate, Within 1 Hour):**

**Monotherapy (Preferred for Stable, Low-Risk):**
- **Cefepime 2g IV q8h** (antipseudomonal β-lactam)
- Alternatives: Meropenem 1g IV q8h, imipenem/cilastatin 500mg IV q6h, piperacillin-tazobactam 4.5g IV q6h

**Add Vancomycin (Empiric) If:**
- **Hemodynamic instability** (septic shock, hypotension)
- **Skin/soft tissue infection** (cellulitis, catheter site)
- **Pneumonia** (on CXR)
- **Positive blood cultures** (Gram-positive cocci, pending ID)
- **Colonized with MRSA**

**DO NOT add vancomycin routinely** (increased toxicity, no mortality benefit unless specific indications)

### **Antifungal Therapy (If Persistent Fever >4-7 Days):**
- **Liposomal amphotericin B 3 mg/kg IV daily**
- **Voriconazole 6 mg/kg IV q12h × 2, then 4 mg/kg IV q12h**
- **Caspofungin 70mg IV × 1, then 50mg IV daily**

**Consider earlier if:**
- High-risk (prolonged neutropenia >7 days, mucositis, prior invasive fungal infection)
- Imaging suggests fungal infection (pulmonary nodules, halo sign)

### **Modify Antibiotics Based on Cultures/Clinical:**
- **Positive cultures:** Tailor to susceptibilities
- **Specific syndromes identified:** Adjust coverage (e.g., anaerobes for intra-abdominal)

### **Duration:**
- **ANC recovered (>500)** + afebrile × 48h + cultures negative → stop antibiotics
- **ANC recovered but fever/infection persists:** Continue antibiotics until infection treated
- **ANC NOT recovered:** Continue antibiotics until ANC >500 (or longer if ongoing infection)

### **G-CSF (Filgrastim):**
- **NOT routinely indicated** for neutropenic fever
- **Consider if:** High-risk features (septic shock, pneumonia, invasive fungal infection, prolonged neutropenia expected >10 days)

### **Risk Stratification:**

**Low-Risk (MASCC Score ≥21):**
- **Outpatient oral** antibiotics possible (ciprofloxacin + amoxicillin-clavulanate)
- **Solid tumor** (not hematologic malignancy)
- **No comorbidities**, hemodynamically stable

**High-Risk:**
- **Hematologic malignancy** (AML, ALL)
- **Prolonged neutropenia expected** (>7 days)
- **Comorbidities** (hypotension, pneumonia, COPD, prior fungal infection)
- **Intensive chemotherapy** (induction, HSCT conditioning)

## Key Points

### **Cefepime = First-Line:**
- **Antipseudomonal** coverage essential (Pseudomonas common, virulent)
- **Monotherapy** adequate for stable, low-risk

### **Vancomycin NOT Routine:**
- **Only add if specific indications** (shock, skin infection, MRSA colonization)
- **NO mortality benefit** if added empirically to all

### **Persistent Fever >4-7 Days:**
- **Add empiric antifungal** (*Candida*, *Aspergillus* risk)
- **Consider CT chest** (fungal pneumonia, nodules with "halo sign")

### **Time is Critical:**
- **Antibiotics within 1 hour** of fever recognition
- **Delay = increased mortality**

### **Clinical Pearls:**
- **ANC <500 + fever:** Cefepime 2g IV q8h (within 1 hour)
- **Add vancomycin:** Only if unstable, skin infection, pneumonia, MRSA colonization
- **Persistent fever >4-7 days:** Add antifungal (amphotericin B, voriconazole, caspofungin)
- **Duration:** Until ANC >500 + afebrile × 48h (minimum)
- **G-CSF:** NOT routine, consider if high-risk features

## Sources

- [IDSA: Neutropenic Fever Guidelines 2024]
- [NCCN: Fever and Neutropenia 2024]

## Media

N/A
